United States Patent 12,209,059: Scope, Claim Structure, and US Patent Landscape for Once-Daily Oral Therapy of Excessive Daytime Sleepiness (EDS)
What does US Drug Patent 12,209,059 claim?
US 12,209,059 is directed to methods of treating Excessive Daytime Sleepiness (EDS) by administering a therapeutically effective amount of a Formula (I) compound, with defined substituent scope (R, x, R1, R2), and with a separate claim track covering enantiomeric forms and high-enantiomeric-purity requirements, including once-daily oral tablet dosing.
The claims as provided establish three core protection dimensions:
- Chemical genus-to-method claims (Formula I and pharmaceutically acceptable salts/esters)
- Enantiomer-specific method claims (substantially enantiopure or predominant-enantiomer mixtures)
- Use-context and dosing format limitations (cause of EDS and once-daily oral tablet dosing; dose range in dependent claims)
How broad is the core chemical scope in Claim 1?
Claim 1 is the principal genus method claim. It requires:
- A method of treating EDS in a subject
- Administration of a therapeutically effective amount of a compound of Formula (I) (or salt/ester)
- Once daily oral tablet administration
Formula I parameterization (Claim 1)
The claim defines R, x, and the variable substituents R1/R2:
R is selected from:
- hydrogen
- lower alkyl (C1-C8)
- halogen (F, Cl, Br, I)
- alkoxy (C1-C3)
- nitro
- hydroxy
- trifluoromethyl
- thioalkoxy (C1-C3)
x is an integer:
- x = 1 to 3
- proviso: when x = 2 or 3, each R substituent can be the same or different (no restriction to symmetry)
R1 and R2 are independently selected from:
- hydrogen
- lower alkyl (C1-C8)
- aryl
- arylalkyl
- cycloalkyl (C3-C7)
Alternative ring-closure definition:
- R1 and R2 can be joined to form a 5- to 7-membered heterocycle substituted with hydrogen, alkyl, or aryl
- heterocycle composition:
- 1 to 2 nitrogen atoms
- 0 to 1 oxygen atom
- the nitrogen atoms are not directly connected with each other or with the oxygen atom
Route and regimen limitation (Claim 1)
- Administration comprises a once daily oral tablet.
Practical read-through for freedom-to-operate: even if Formula (I) coverage is broad at the structural definition level, the claim restricts infringement to EDS treatment via a once-daily oral tablet regimen.
What do dependent claims narrow to “simple” embodiments?
The claim set includes straightforward genus-to-specific narrowing steps:
- Claim 2: R = hydrogen; x = 1
- Claim 3: R, R1, R2 are all hydrogen; x = 1
These are not separate chemical entities; they are specific parameter instantiations of the Formula (I) genus. They function as narrower anchors that catch variants that may fall within the same scaffold but are easier to map in prosecution/validity arguments.
How does the enantiomer track expand or tighten the scope? (Claims 4–16)
Claim 4 is a parallel independent claim to Claim 1, but instead of a general Formula (I) compound, it covers enantiomeric forms:
- Treat EDS by administering a therapeutically effective amount of:
- an enantiomer of Formula I substantially free of other enantiomers, or
- an enantiomeric mixture where one enantiomer predominates
- or pharmaceutically acceptable salt/ester
- and once daily oral tablet
Enantiomer predominance thresholds (explicit)
The claims specify numeric predominance levels:
- Claim 7: predominance ≥ about 90%
- Claim 8: predominance ≥ about 98%
- Claim 12: predominance ≥ about 90%
- Claim 13: predominance ≥ about 98%
Specific stereochemical embodiments (Claims 9–11, 14–16)
The enantiomeric claim track then narrows to Formula Ia and named stereoisomers:
- Claim 9: enantiomer is an enantiomer of Formula Ia (or salt/ester)
- Claim 10: enantiomer is the (R) or (D) enantiomer
- Claim 11: enantiomer is the (S) or (L) enantiomer
Then a more explicit stereochemical identity appears:
- Claim 14: the substantially enantiopure species is
(R)-(beta-amino-benzenepropyl) carbamate (or mixture where it predominates)
- Claim 15: predominance of (R)-(beta-amino-benzenepropyl) carbamate ≥ about 90%
- Claim 16: predominance ≥ about 98%
What changes between Claim 1 and Claim 4?
- Claim 1 protects any Formula (I) species that fits the substituent definition.
- Claim 4 protects stereochemical variants, using enantiopurity/predominance thresholds and specific enumerated enantiomers tied to Formula Ia and named carbamate.
Business implication: Claim 4 creates an additional infringement lane even if a competitor attempts to design around by changing stereochemistry or using enriched mixtures, as long as the mixture meets the ≥90% or ≥98% predominance language and is administered as a once-daily oral tablet for EDS.
How does the patent narrow the clinical “cause” of EDS? (Claim 17–18)
Claim 17 limits infringement to patients where the cause of EDS is chosen from a long enumerated list including:
- CNS pathologic abnormalities, stroke, narcolepsy, idiopathic CNS hypersomnia, sleep deficiency, sleep apnea
- obstructive sleep apnea
- insufficient nocturnal sleep
- chronic pain, acute pain
- Parkinson’s disease
- urinary incontinence
- multiple sclerosis fatigue
- ADHD
- Alzheimer’s disorder
- Major Depression
- Bipolar Disorder
- cardiac ischemia
- circadian pacemaker misalignment, jet lag, shift work
- sedating drugs
Claim 18 narrows further:
- cause of EDS is narcolepsy
Operational read-through: the broader causation list in Claim 17 and the narcolepsy-specific narrowing in Claim 18 can influence enforcement strategy and patient selection in any litigation. It also affects how an applicant or generic designer would frame clinical labeling and indications.
What does the dosing claim language cover? (Claim 19)
Claim 19 imposes a specific dose range tied to the once-daily oral tablet of:
- (R)-(beta-amino-benzenepropyl) carbamate
Dose range:
- about 0.1 mg/day to 1000 mg/day
This claim anchors both form (once-daily oral tablet) and quantity for the named compound.
Claim scope summary table
| Claim |
Core subject matter |
Key compound scope |
Key administration limitation |
Key narrowing elements |
| 1 |
Treat EDS method |
Formula (I) (R, x, R1, R2; salts/esters) |
Once daily oral tablet |
Formula parameters and heterocycle option |
| 2 |
Dependent |
R = H; x = 1 |
Once daily oral tablet |
Minimal substituent configuration |
| 3 |
Dependent |
R, R1, R2 = H; x = 1 |
Once daily oral tablet |
Minimal substituent configuration |
| 4 |
Treat EDS method |
Enantiomer of Formula I or predominant mixture; salts/esters |
Once daily oral tablet |
Enantiopurity/predominance concept |
| 7, 12 |
Dependent |
Enantiomer predominance |
Once daily oral tablet |
≥ about 90% predominance |
| 8, 13 |
Dependent |
Enantiomer predominance |
Once daily oral tablet |
≥ about 98% predominance |
| 9–11 |
Dependent |
Enantiomer of Formula Ia; (R)/(D) or (S)/(L) |
Once daily oral tablet |
Explicit stereochemical direction |
| 14–16 |
Dependent |
(R)-(beta-amino-benzenepropyl) carbamate |
Once daily oral tablet |
≥ about 90% or 98% |
| 17 |
Dependent |
EDS cause limitation |
Once daily oral tablet |
Long enumerated causes list |
| 18 |
Dependent |
EDS cause = narcolepsy |
Once daily oral tablet |
Narrow indication |
| 19 |
Dependent |
Named compound (R)-(beta-amino-benzenepropyl) carbamate |
Once daily oral tablet |
Dose range 0.1–1000 mg/day |
What is the likely patent landscape shape in the US?
With only the claims provided, the landscape can be assessed at the scope architecture level rather than by enumerating every in-force patent and related application publication. The claim set indicates a landscape dominated by:
- Method-of-use patents for EDS treating indications
- Stereochemistry-based exclusivity around a specific enantiomer and carbamate identity
- Product form and regimen constraints (once-daily oral tablet)
- Subpopulation targeting through “cause of EDS” language and narcolepsy-specific dependency
Landscape risk vectors for competitors
From an infringement-mapping perspective, the main risk vectors created by this claim set are:
- Stereochemical entry risk: any product containing an enantiomer meeting ≥90% or ≥98% predominance and administered as a once-daily oral tablet for EDS risks falling into Claim 4 and its dependent rails.
- Named enantiomer identity risk: if the product corresponds to (R)-(beta-amino-benzenepropyl) carbamate (or a predominating mixture) it triggers Claim 14 to Claim 19 dose/form constraints.
- Patient indication and labeling risk: the causation list and narcolepsy dependency can be used to narrow or target enforcement to particular clinical contexts even where “EDS” broadly overlaps with other hypersomnolence diagnoses.
- Dosage regime risk: dose range language (Claim 19) can be used as a compliance yardstick for design-around: dosing outside the range or switching dosing frequency/route are the practical levers created by claim text.
Where are the clearest “design-around” levers in the claim language?
1) Break the regimen/form: once-daily oral tablet
Every independent claim shown includes the condition that administration comprises a once daily oral tablet. If a competitor uses:
- non-oral route, or
- oral but not once-daily tablet format, or
- once-daily but not “tablet” dosage form (depends on legal interpretation),
then the literal scope of these claims is narrowed.
2) Break the stereochemical threshold
Claim 4 depends on substantial freedom from other enantiomers or a predominating enantiomer mixture, with explicit ≥90% and ≥98% predominance dependents. A competitor that avoids those thresholds can attempt to exit the literal reach of those dependent limitations, though the independent enantiomer concept still matters.
3) Break the named stereochemistry identity
Claim 14–16 narrows to the explicit carbamate identity (R)-(beta-amino-benzenepropyl) carbamate. If a product uses a different enantiomer identity than what the claim maps, Claim 14–16 rails do not apply.
4) Break the EDS “cause” mapping
Claim 17–18 narrow causation to enumerated conditions and narcolepsy. A competitor targeting different EDS etiologies can attempt to reduce exposure to those dependent claims, while independent EDS treatment claims still remain relevant.
What does the claim set imply about enforceability focus?
The structure suggests enforceability is likely to concentrate on:
- pharmacologically active ingredient in an enriched enantiomeric form
- once-daily oral tablet formulation
- and EDS indication conduct (including narcolepsy-specific patient populations)
The claims do not rely solely on broad chemical coverage; they also lock onto use and product regimen. That combination raises the bar for competitors attempting to repackage the same pharmacology through different dosing logistics.
Key Takeaways
- US 12,209,059 claims EDS treatment via once-daily oral tablet administration of Formula (I) compounds and explicitly defined enantiomeric forms of Formula I/Formula Ia.
- The chemical genus is defined by substituent lists for R, x, R1, R2, including a heterocycle option.
- A parallel enantiomer track creates enforceable lanes using predominance thresholds (≥90% and ≥98%) and explicit stereochemical embodiments, culminating in (R)-(beta-amino-benzenepropyl) carbamate (and salts/esters).
- The landscape risk for entrants is driven by stereochemical enrichment, once-daily oral tablet regimen, and EDS patient selection via enumerated causes and narcolepsy dependency.
- Dependent claims add guardrails on dose range (0.1 mg/day to 1000 mg/day) for the named carbamate, tightening the product design compliance space.
FAQs
1) Does the patent require a specific molecule, or can it cover a class?
It covers a class defined by Formula (I) parameters in Claim 1, but it also includes a separate independent claim track for enantiomers of Formula I/Formula Ia and explicitly named embodiments such as (R)-(beta-amino-benzenepropyl) carbamate.
2) What does “once daily oral tablet” do to the claim scope?
It functions as a required administration limitation across the core claims shown. It ties infringement to a specific dosing format and schedule rather than EDS treatment in any arbitrary form.
3) How do the 90% and 98% thresholds matter?
They define dependent-claim predicates for the enantiomer predominant mixture. If a product’s enantiomer composition does not meet those predominance thresholds, those dependent rails are harder to assert based on the text provided.
4) Is narcolepsy a required indication?
Not for the independent EDS method claims shown, but Claim 18 narrows a dependent clause to cases where the cause of EDS is narcolepsy.
5) Does the dose range apply only to the named compound?
Yes. Claim 19 ties the dose range explicitly to the once-daily oral tablet of (R)-(beta-amino-benzenepropyl) carbamate.
References
[1] United States Patent No. 12,209,059 (claims as provided by user).
